Amid Novo Nordisk and Pfizer’s whiplash contest for obesity biotech Metsera, Novo’s CEO has, quite literally, told its rival to put its money where its mouth is. | Amid Novo Nordisk and Pfizer’s ...
Women’s health company Organon is selling off its postpartum uterine bleeding or hemorrhage system to Laborie Medical ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
Sana Biotechnology, CAMP4 Therapeutics and Crinetics Pharmaceuticals have all used the third quarter to refocus their ...
The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...
Last month, a study showed Science Corp.’s PRIMA BCI retinal implant restored some vision to people with severe age-related macular degeneration. Meanwhile, Elon Musk’s Neuralink earlier this year ...
In the study, published in Science Translational Medicine on Nov. 5, researchers identified proteins expressed on the surface ...
Eli Lilly’s star oral GLP-1 candidate orforglipron and Novo Nordisk’s Wegovy (semaglutide) were named voucher winners in a ...
More than a year and a half into Cullinan Therapeutics’ pivot from a CD19-focused oncology company to a hybrid autoimmune player, the biotech is parting ways with a pair of cancer programs. | More ...
Axsome Therapeutics has wrapped its hands around an epilepsy candidate from AstraZeneca through an acquisition of Avenue ...
UroGen is handing an anti-CTLA-4 antibody back to Agenus after concluding phase 1 data for the bladder cancer drug didn’t ...
China is set to ease restrictions on some Illumina products, giving the sequencing giant a partial reprieve. | China is set to ease restrictions on some Illumina products, giving the sequencing giant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback